
ONCY Stock Forecast & Price Target
ONCY Analyst Ratings
Bulls say
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company that is developing pelareorep, an immunotherapeutic agent aimed at enhancing the immune system's ability to combat cancer, which could lead to significant advancements in treatment efficacy. The potential for strategic partnerships to accelerate the registration process for pelareorep may extend the company's operational timeline and unlock substantial shareholder value. Additionally, the external validation received from key opinion leaders enhances Oncolytics’ credibility in the industry, reinforcing the positive outlook for future growth and development of its product pipeline, including treatments for breast and gastrointestinal cancers.
Bears say
Oncolytics Biotech Inc. is still in the clinical stage and has yet to achieve significant commercial success, which raises concerns about its long-term viability and the sustainability of its financial health. The development of its lead candidate, pelareorep, and the other pipeline projects for various cancers carry high risks typical of early-stage biotechnology companies, such as potential delays in clinical trials and regulatory approvals that could hamper revenue generation. Additionally, the company’s reliance on funding from equity markets may expose it to dilution risks and could impact its financial stability if investor sentiment weakens.
This aggregate rating is based on analysts' research of Oncolytics Biotech, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ONCY Analyst Forecast & Price Prediction
Start investing in ONCY
Order type
Buy in
Order amount
Est. shares
0 shares